Dr. Dilan A. Patel, MD
Medical Oncology (Medical Oncology Physician)
11133 Dunn Rd, Div Im Medical Oncology
Saint Louis, MO 63136
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 315
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Tennessee, Hsc, College of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2020020085 -
Internal Medicine Physician
MO license 2020020085
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Memorial Hospital Belleville, IL
- Christian Hospital Northeast Saint Louis, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
- Washington University Physicians in Illinois Inc (175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 315
- Services billed
- 30,302
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 107 | 36 |
| Established patient office or other outpatient visit, 30-39 minutes | 66 | 51 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | 16 |
| Injection of drug or substance under skin or into muscle | 19 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 17 | 17 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Saint Louis, MO | 82 |
| Prednisone Other prescribers in Saint Louis, MO | 56 |
| Hydroxyurea Other prescribers in Saint Louis, MO | 41 |
| Brukinsa (zanubrutinib) | 40 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 30 |
| Venclexta (venetoclax) | 27 |
| Imbruvica (ibrutinib) | 26 |
| Gabapentin Other prescribers in Saint Louis, MO | 26 |
| Revlimid (lenalidomide) | 22 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $103 in total to this clinician.
| Adc Therapeutics America, Inc. | $103 |
|---|
| Food and Beverage | $103 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $337,169 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 openlabel study of PF07901801 in combination with glofitamab after a fixed single dose of obinutuzumab in participants with relapsedrefractory diffuse large b cell lymphoma not eligible for stem cell trans…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.